Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: Core–shell nanoparticle carrier and drug release response

A novel magnetic drug-targeting carrier consisting of magnetic nanoparticles encapsulated with a smart polymer with characteristics of controlled drug release is described. The carrier is characterized by functionalized magnetite (Fe 3O 4) and conjugated therapeutic agent doxorubicin, which is encap...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta biomaterialia 2007-11, Vol.3 (6), p.838-850
Hauptverfasser: Zhang, J., Misra, R.D.K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A novel magnetic drug-targeting carrier consisting of magnetic nanoparticles encapsulated with a smart polymer with characteristics of controlled drug release is described. The carrier is characterized by functionalized magnetite (Fe 3O 4) and conjugated therapeutic agent doxorubicin, which is encapsulated with the thermosensitive polymer, dextran- g-poly( N-isopropylacrylamide- co- N, N-dimethylacrylamide) [dextran- g-poly(NIPAAm- co-DMAAm)]. The surface of magnetite nanoparticles was functionalized by chemical bonding with 3-mercaptopropionic acid hydrazide (HSCH 2CH 2CONHNH 2) via Fe–S covalent bonds. The anticancer therapeutic drug, doxorubicin, was attached to the surface of the functionalized magnetic nanoparticles through an acid-labile hydrazone-bond, formed by the reaction of hydrazide group of HSCH 2CH 2CONHNH 2 with the carbonyl group of doxorubicin. The dextran- g-poly(NIPAAm- co-DMAAm) smart polymer exhibits a lower critical solution temperature (LCST) of ∼38 °C, which is representative of a phase transition behavior. This behavior allows for an on–off trigger mechanism. At an experimental temperature lower than LCST, the drug release was very low. However, at a temperature greater than LCST, there was an initially rapid drug release followed by a controlled released in the second stage, especially, in the mild acidic buffer solution of pH 5.3. The release of drug is envisaged to occur by the collapse of the encapsulated thermosensitive polymer and cleavage of the acid-labile hydrazone linkage. The proposed carrier is appropriately suitable for magnetic targeting drug delivery system with longer circulation time, reduced side effects and controlled drug release in response to the change in external temperature.
ISSN:1742-7061
1878-7568
DOI:10.1016/j.actbio.2007.05.011